Ray Therapeutics

General InformationRay Therapeutics is a deep-tech biotech company focused on developing novel therapeutic approaches, likely in the longevity or precision medicine space based on its positioning in the biotechnology sector.

Funding & FinancialsUnable to confirm current funding details from available sources; the company appears to be in early-to-mid stage development based on typical deep-tech biotech trajectories.

Leadership & TeamSpecific leadership information for Ray Therapeutics could not be verified from current publicly available sources.

Recent ActivityRecent activity and product developments for Ray Therapeutics are not immediately available in accessible public records; the company may be operating in stealth mode or with limited public disclosure typical of early-stage biotech ventures.

Highlights

Total Raised

—

2 rounds

Latest Round

—

Apr 24, 2026

Stage

—

deep-tech

Employees

—

Headquarters

—

News Coverage

—

Talent Signals

—

SEC Filings

—

Backers

4BIO Capital

Adage Capital Management

Deerfield Management

Franklin Templeton

Invus

Janus Henderson Investors

Marshall Wace

MRL Ventures Fund

Norwest

Novo Holdings

Platanus

Funding History

$125

2026

Series B

2026

Series B

SEC Form D Editorial

Apr 24, 2026

—Series B · Editorial

Ray Therapeutics develops optogenetic therapies to restore sight in retinal diseases including retinitis pigmentosa, securing Series B for late-stage clinical development.

Apr 22, 2026

$125 millionSeries B · Editorial

Investors: Janus Henderson Investors, Adage Capital Management, Franklin Templeton, Invus, Marshall Wace, 4BIO Capital, Deerfield Management, MRL Ventures Fund, Norwest, Novo Holdings, Platanus

Clinical-stage biopharmaceutical company developing optogenetic therapies for vision restoration in retinal degenerative diseases raised $125M Series B.

Similar Companies 6

Knightscope Cobalt Robotics Bechtle PSB GmbH Quarero Robotics MICROPURE GENOMICS INC.